How Pharma Benefits with
Mobile Patient Engagement
Patient Engagement Mobile Apps for Pharma
The majority (60%) of clinicians and the healthcare industry leaders believe effective patient engagement brings serious impact on the quality of care and can substantially decrease the costs in the system, according to the survey held by NEJM Catalyst.
There’s one more category of healthcare entities that gets considerable benefits from patient engagement mobile tools - pharmaceutical companies. Let’s see how these benefits spin around pharma and contribute to the industry results.
In this article you find out:
- How medical representatives armed with mobile apps for patient engagement become more productive.
- Why doctors are motivated to prescribe medications and treatments paired with apps for remote monitoring, control and self-tracking for patients.
- What happens when you integrate mHealth apps and other digital tools into trials and researches.
How patient engagement mobile apps enhance medical representative’s efforts
Even though it’s medical representatives who drive the adoption of pharma products by clinics, hospitals and individual doctors, less than a half (43%) of MRs can make it through the receptionists, and only 7% will get a chance to talk to a doctor for at least 2 minutes. The statistics of MR efficiency is often not encouraging, to be fair.
“Half of cancer specialists are saying that they would directly interact only on new products with MRs. 47% prefer to have communication over the email, 20% decline interaction with MRs, 40% do not meet MRs without prior appointments.” CMI Communication Media Research.
Nevertheless, MRs play an essential role as the primary channel to translate the benefits of pharma products and influence on major adopters - doctors and hospitals.
Today, an mHealth app that improves engagement both for physicians and patients becomes a valuable tool in MR’s hands. First of all, it goes beyond any brochure to explain and visualize the effects and functions of any, even the most complex medical product. Secondly, digital tools augment the benefits of medical products, for example by remote monitoring features of ability to collect important patient data. And finally, introducing mobile patient engagement into healthcare experience promises better efficiency, for doctors, clinics, associations and the whole industry in general.
Therefore, such companies as Pfizer, Merck & Co. and Novartis actively equip their representatives with innovative digital tools to strengthen their credibility and relevance, reconnect with target audiences and improve the infrastructure around medical products.
Are you looking for a skilled team experienced in both custom mobile applications development and healthcare and wellness technologies? Contact Digiteum team to get a free quote for your project. We have built digital systems for hospitals, foundations and numerous pharmaceutical companies, including Takeda, Sanofi, Merck. Check our eHealth portfolio for more information.
In pursue to reach more healthcare professionals and consumers, Merck & Co. issued a dual healthcare app -
Another pharmaceutical leader, Pfizer, also counted on patient engagement mobile apps to reconnect with certain demographics. In particular, the company started the initiative
Translating the benefits of the apps that provide valuable content or enable doctor-to-patient connection in one thing. Try marketing and explaining something as complex as a medical device.
Abbott addressed this issue to digital creating its
Another device by Roche,
Why patient engagement mobile applications are indispensable for doctors
Medical representatives may be the major channel to market pharmaceutical products. However, it’s doctors who influence the rate of prescriptions and caregivers who monitor product adoption and adherence. Therefore, many pharma companies create efficient medical apps for physicians to contribute to the efforts of this category of users. Apparently, these tools are here to stay.
First of all, digital can and already tackles some of the most lasting problems in healthcare environment - lack of awareness among patients and scarcity of accessible credible content about diseases and treatments, communication barriers between doctors and patients caused by over bureaucratized procedures, insufficient health and social care services, especially in rural areas, to name a few.
Secondly, digital tools are receiving more trust among users. Next-gen healthcare apps for patients with personalization features, user-friendly design and adaptive interfaces become more and more ubiquitous among different categories of users, including the elderly and people with special needs.
“The number of users who download mHealth apps is estimated to reach 2.6 billion by 2020, with 551 million ending up as active users. In general, mHealth app market is going to reach $31 billion in revenue by 2020.” Research2Guidance report.
Finally, these tools bring both patients and doctors previously inaccessible advantages, such as remote treatment monitoring on a day-to-day basis and real-time symptom and health conditions tracking.
Here come some of the examples that illustrate how pharmaceutical companies support doctors’ and caregivers’ efforts.
One of industry leaders, Novartis built
Another healthcare app designed for Merck & Co. - ChemoDiary - is focused on cancer patients undergoing complex chemotherapy. This mobile app collects symptoms and side effects during chemo treatment, encourages patients to self-track their reaction to medication, maintain treatment calendar and share personalized medical condition reports with authorized healthcare providers. As a result, doctors receive relevant, up-to-date information on how patients react to chemo medication and can remotely follow every step of a complex treatment process.
What patient engagement mobile apps have to do with clinical trials and research
Pharmaceutical companies conduct thousands of clinical trials and researches annually. It’s a long way for drugs and medical procedures to go from R&D to tried-and-true stage, and a complex process that involves multiple players - sponsors, investigators, doctors, nurses, caregivers and patients. The last two make the core, as caregivers oversee the compliance and patients act as the subjects to provide data.
“Patients and caregivers are the heart and soul of this research, no new medical advances would be made without them.” Craig Lipset, Head of Clinical Innovation at Pfizer Worldwide Research & Development.
No need to explain why clinical trial data is a valuable asset for every investigation. Its volume determines the term needed to test a drug or medical procedure, while its quality guarantees the credibility and accuracy of trial results.
In this context, modern digital tools exceed any other means to collect data. For example patient engagement mobile apps, especially the ones integrated with wearable devices or medical sensors and trackers, can collect diverse data about patient health conditions in real time. Meanwhile, powerful analytics based on smart algorithms can efficiently process this data and turn it into trial results.
Therefore, more pharmaceutical companies equip their research groups with digital tools to collect intake and symptom data, track patient adherence to ensure the accuracy of trial data and provide easy access to up-to-date research content and trial results.
One of the most vivid examples of a trial companion app is
5-star patient engagement app by a technology company Medidata Solutions,
Another tool Excedrin Migraine Experience by GlaxoSmithKline doesn’t collect data on Excedrin intake, but makes an attempt to visualize each patient’s migraine experience. Integrated AR capabilities allow app users model their personal migraine symptoms - aura, trumping headache, disorientation, floating spots, sensitivity to light - and share this data with others. This data can make a tremendous impact on our understanding of migraines and contribute to creating better solutions in this field.
Apart from helping patients share their symptoms and follow trial directions, pharmaceutical companies invest into the tools to provide trial data and easy access to credible medical content for doctors, caregivers, researchers and patients.
For example, the above mentioned GlaxoSmithKline developed an app
These examples are numerous, as each pharmaceutical company, be it big players like Pfizer, Merck & Co., Novartis, Roche or smaller enterprises, does its best to reap the benefits of developing technologies and improve its products and processes as fast and efficiently as possible. Therefore, mHealth and next-gen patient engagement mobile apps will remain on the radar of pharma companies, and the decision-makers in the industry will stay among major implementers and adopters of modern eHealth solutions.